Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
Clinical trial NCT07032532 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07032532
- Sponsor
- Sun Yat-sen University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2028-12-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.